Nivolumab/Ipilimumab Combo Nears EU Approval for Frontline RCC

November 16, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC), according to Bristol-Meyers Squibb (BMS), the developer of both immunotherapy agents. “There remains a high unmet medical need for patients with advanced … (leggi tutto)